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The cell-surface receptor for interleukin-2 (IL-2) consists of two unlinked polypeptides of 55 and 75 kDa (p55, p75). 
The monoclonal antibody antiTac binds to p55 alone. We show here that the binding of either IL-2 or antiTac to the 
surface of T lymphocytes triggered the generation of cAMP. Reagents which activate adenyl cyclase by stimulation of 
its guanine nucleotide-binding protein (Gs) also stimulated increases in cAMP. All of the above reagents, and cAMP 
itself, stimulated the turnover of phosphate residues bound to serine and threonine residues of an 85 kDa protein. The 
data provide evidence that the binding of ligands to the p55 component of the IL-2 receptor generates a biochemical 
signal by the stimulation of adenyl cyclase via Gs, and that the consequent generation of cAMP and activation of cAMP- 
dependent protein kinase modulates the turnover of p85-bound phosphate groups. 
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1. INTRODUCTION 
The further proliferation of lymphocytes pre- 
activated by antigen or lectins is stimulated by the 
binding of the lymphokine interleukin-2 (IL-2) to 
a specific cell surface receptor [1]. The IL-2 recep- 
tor consists of two unlinked glycoprotein chains of 
55 kDa (p55) and 75 kDa (p75) [2]. While the 
biochemical mechanisms by which IL-2 binding 
transduces its mitogenic signal are poorly 
understood, IL-2 stimulated protein phosphoryla- 
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tion has been demonstrated in a variety of 
IL-2-sensitive cells [3-7]. Using a permeabilised 
lymphocyte system incubated with [32p]ATP, we 
have shown that both IL-2 and antiTac, a 
monoclonal antibody directed against p55 [8], 
stimulated the labelling of an 85 kDa protein (p85) 
on serine and threonine residues [3]. We have here 
explored the mechanism by which these ligands 
stimulate p85 labelling, and show that antiTac, like 
IL-2 itself [9], triggers a transient elevation of lym- 
phocyte cyclic AMP concentrations. Furthermore, 
two agents which activate guanine nucleotide- 
binding regulatory proteins (G-proteins), the 
fluoroaluminate ion (AIFg [10]) and guanosine 
5'-[7-thio]triphosphate (GTP[S]) elevated lym- 
phocyte cAMP levels and also triggered the 
phosphorylation of p85. Taken together, the data 
suggest that both IL-2 and antiTac can trigger the 
phosphorylation f p85 by a mechanism involving 
cAMP elevation, and imply a role for the p55 com- 
ponent of the IL-2 receptor in transducing a 
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biochemical signal across the lymphocyte cell 
membrane. 
2. MATERIALS AND METHODS 
2.1. Cells 
Lymphocytes were purified from the peripheral blood of 
healthy volunteers and pre-activated by treatment with 
phytohaemagglutinin for 5days [11]. The resulting cells were 
entirely dependent on IL-2 for further proliferation. IL-2 
mitogenesis was estimated by measuring the incorporation f
[3H]thymidine (41Ci'mmo1-1, Amersham, England) as 
described [11]. 
2.2. cAMP assays 
These were carried out by a radioimmunoassay procedure as 
described [9]. Duplicate stimations of cAMP did not vary by 
more than 5%. 
2.3. Detection of ligand-stimulated protein phosphorylation in 
permeabilized cells 
This procedure has been described in detail previously [3,12]. 
Briefly, lymphocytes (108 cells-m1-1) were treated with L-~- 
lysophosphatidylcholine (1 mg-ml-t). This procedure nders 
the cells permeable to small molecules without perturbing their 
morphology orability to synthesize DNA, RNA or protein for 
at least 3 h [13]. The permeable c lls were incubated with 
[T-32P]ATP (New England Nuclear, England; 3000Ci. 
mmol -l) together with IL-2 or other agents for 3 rain. 
Radiolabelled proteins were separated by polyacrylamide g l
electrophoresis in the presence of SDS and detected by 
autoradiography. Autoradiograms were scanned using a Joyce- 
Loeb] Chromoscan II. 
2.4. Reagents 
Human recombinant IL-2 was from Amersham; antiTac was 
kindly provided by Dr T.A. Waldmann, NIH, Bethesda, MD, 
USA. 
3. RESULTS AND DISCUSSION 
We have shown previously that the binding of 
IL-2 to its receptor on intact IL-2 responsive cells 
triggers the rapid generation of cAMP [9]. These 
results are confirmed here (fig.lA). In addition, 
the binding of anfiTac also triggered the transient 
elevation of  cAMP (fig.lA). The AlF~ anion is 
known to activate adenyl cyclase via stimulation of  
Gs, the G-protein which positively regulates its ac- 
tivity [14]. This reagent also triggered the transient 
elevation of cAMP in lymphocytes (fig.lB), sug- 
gesting that adenyl cyclase regulated via a G- 
protein was present in these cells. IL-2, antiTac, 
AIF~ and GTP[S] (another direct activator of  Gs 
[15]), also stimulated cAMP elevation when added 
to the permeabilised lymphocyte system used to 
measure ligand-stimulated protein phosphoryla- 
tion (fig. 1B,C), indicating that the putative coupl- 
ing between the IL-2 receptor and adenyl cyclase 
remained intact in the permeable cell system. 
Each experiment depicted in fig. 1 was repeated 
on at least three occasions and invariably showed 
a statistically significant increase in cAMP levels in 
response to each reagent ested. However, the bi- 
phasic response in cAMP levels clearly seen in 
some experiments (fig.lA,D) showed some 
variability when cells from different donors were 
used, with respect o both the time and relative 
magnitude of each peak. 
IL-2 binding to permeabilized lymphocytes in 
the presence of [32p]ATP stimulated the labelling 
of  an 85 kDa protein (p85, fig.2A). Maximal 
labelling of p85 occurred within 3 rain of IL-2 ad- 
dition (not shown). The relationship between rapid 
ligand-stimulated protein phosphorylation and 
mitogenesis is difficult to establish, due to the 
complexity of the pathways connecting early 
events to the initiation of DNA replication [16]. 
However, the dependence of p85 on IL-2 concen- 
tration paralleled the mitogenic dose response to 
the same ligand (fig.2B), suggesting a role for p85 
phosphorylation (or for the phosphotransferase 
system which phosphorylates p85) in the early 
steps of  IL-2 mitogenesis. 
IL-2 stimulated labelling of p85 was clearly 
detected when IL-2 was added to intact lym- 
phocytes which were then washed free of unbound 
IL-2, permeabilized and incubated with [32p]ATP 
(fig.2C). p85 labelling was evident when cells were 
labelled between 5and 30 rain following IL-2 addi- 
tion to intact cells, but was reduced to nearly con- 
trol levels at 60 rain. This suggests that p85 
labelling was due to an  accelerated turnover of  
protein-bound phosphate rather than to a single 
stable phosphorylation event. This conclusion has 
been confirmed by 'chasing' the radiolabel in p85 
by incubation with unlabelled ATP (not shown). 
The experiment shown in fig.2C also suggests that 
p85 labelling is not an artefact due to addition of 
IL-2 to permeabilized cells, since labelling was 
elicited by addition of  IL-2 to intact cells which 
were subsequently washed free of  unbound IL-2 
prior to permeabilization and incubation with 
[32p]ATP. 
In addition to IL-2 antiTac, AIF~ and GTP[S] 
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Fig.l .  Elevation of  cAMP levels in lymphocytes treated with IL-2, antiTac, AIF~ or GTP[S]. Intact iymphocytes (A,B) at 106 
cells-ml -m or permeable lymphocytes (C,D) at 10 a cells .ml -~ were treated with 75 U .ml -~ IL-2 (o), 1 : 100 dilution of  antiTac ascites 
(e), AIF~ (10 mM NaF + 1/~M AICl3) (6)  or I mM GTP[S] (A). cAMP was estimated at the times indicated and are expressed as 
a percentage of  cAMP content in untreated control cells which were sampled at each time point, cAMP levels in control cells are 
indicated as mean + SD (open bar) on each figure. Actual mean values in control cells varied between 324 and 513 fmol/106 cells. 
The effects of  each ligand were found to be significantly different compared to the control by two-way analysis of  variance (p < 0.001 
for A and C, p < 0.005 for B and D). 
also stimulated p85 phosphorylation as did the 
direct addition of cAMP (fig.3), implying that the 
activation of cAMP-dependent protein kinase 
either directly or indirectly stimulated the turnover 
of p85-bound phosphate. Phosphoamino acid 
analysis (not shown) of p85 labelled in response to 
each of these reagents confirmed our previous con- 
clusions [3] that labelling occurred on serine and 
threonine residues. By contrast, two reagents 
which stimulate other phosphotransferase systems 
did not trigger p85 labelling. 12-O-Tetradecanoyl- 
phorbol-13-acetate (TPA) which stimulates protein 
kinase C (PKC) [17] did not elicit p75 labelling 
(fig.3) suggesting that the kinase C system does not 
play a role in this aspect of IL-2 mitogenesis. This 
conclusion is confirmed by our observation that 
the Ca 2+ chelator EGTA, which inhibits PKC, did 
not affect p85 labelling stimulated by either IL-2 or 
antiTac (not shown). It is unlikely that PKC par- 
ticipates in IL-2 signal transduction i  normal lym- 
phocytes, since IL-2 did not provoke the turnover 
of inositol ipids with the consequent generation of 
diacylglycerol [9,18,19], the physiological ac- 
tivator of PKC [17]. By contrast, PKC appears to 
play a crucial role in the early stages of lymphocyte 
mitogenesis [18,20,21]. cGMP, which activates a
specific GMP-activated kinase, also failed to elicit 
p85 labelling (fig.3). In conclusion, we have shown 
here that the binding of either IL-2 or the mono- 
clonal antibody antiTac, which binds only the p55 
component of the IL-2 receptor, triggers the 
generation of cAMP in both intact and permea- 
bilised lymphocytes and stimulates the turnover of 
phosphate bound to serine and threonine residues 
of an 85 kDa protein. Since p85 labelling can also 
be elicited by agents which directly activate G- 
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Fig.2. (A) Lymphocytes were permeabilized and incubated with [32P]ATP in the presence of: 1, no additions; 2, 10/~g-ml-~ BSA 
albumin; 3, 10/zg'm1-1 BSA + 75 U.ml -~ IL-2. Labelled proteins were separated by gel electrophoresis and visualized by 
autoradiography. Migration of molecular mass markers i indicated by arrows. The long arrow indicates the position of p85. (B) Dose 
responses of [3H]thymidine incorporation (e) and p85 labelling (B) in response to increasing concentration f IL-2. p85 labelling was 
quantitated by densitometric scanning of autoradiogram. ((2) Intact lymphocytes were incubated with 75 U. ml-l IL-2 for the indicated 
times, then washed, permeabilized and incubated with [nP]ATP for 3 min. Scans of the 85 kDa region of the autoradiograms are 
shown. 
proteins and consequently stimulate the generation 
of cAMP, or by the addition of cAMP itself, we 
suggest hat the binding of either IL-2 or antiTac 
to the p55 component of the IL-2 receptor is 
coupled to the stimulation of adenyl cyclase via a 
G-protein, presumably the well-characterised Gs 
[14]. 
Whereas IL-2 is mitogenic for lymphocytes, an- 
tiTac is not, and under some experimental condi- 
tions blocks IL-2 mitogenesis [22]. Therefore, 
additional signals consequent to IL-2 binding to 
the p75 receptor component must also be of impor- 
tance in securing the commitment of lymphocytes 
to mitosis. The stimulation of phosphorylation of
a 75 kDa protein on unspecified amino acids 
following IL-2 addition to antiTac immunoprecipi- 
tates of lymphocyte membranes has been reported 
and may represent ligand-stimulated autophospho- 
rylation of the p75 receptor component [6]. In ad- 
dition, IL-2 binding has been shown to increase the 
phosphorylation on tyrosine residues of several 
proteins, suggesting the direct or indirect activa- 
tion of tyrosine-specific protein kinases [7]. Taken 
together with the IL-2-stimulated phosphorylation 
of 63 and 68 kDa proteins on serine and threonine 
residues [4,5] it is likely that signalling via the IL-2 
receptor involves the activation of multiple phos- 
photransferase systems. This complexity of the 
signalling mechanisms is also evident in other 
growth factor systems [16]. 
The role of the p55 IL-2 receptor component in 
signalling is controversial. Dose response studies 
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Fig.3. (A,B) Labelling of p85 by [S2p]ATP in response to 
various reagents. The final concentrations were: IL-2, 
75 U'ml-l; AIF~, 10 mM NaF + 1/~M Alas; GTP[S], 1 mM; 
TPA, 100 nM; cAMP, 1/LM; cGMP, 1/LM. Densitometric 
scans of each lane of the autoradiograms are shown. 
using IL-2 in the presence or absence of  antiTac 
have led to the suggestion that the only role o f  p55 
is to co-operate with the p75 component in order 
to generate a high affinity IL-2 binding site and 
that signal transduction is mediated by p75 alone 
[20]. However,  fibroblasts expressing p55 in the 
absence of  p75 can respond mitogenically to IL-2 
suggesting that p55 alone is capable o f  transducing 
a signal across the plasma membrane [23]. The 
data reported here also suggest strongly that the 
binding of  ligands to the p55 component of  the 
IL-2 receptor is capable o f  generating biochemical 
signals within the cell. The precise role o f  these 
signals in the complex cascades of  events leading to 
the initiation of  mitosis remain to be elucidated. 
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